<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TERBUTALINE SULFATE- terbutaline sulfate injection, solution </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>Terbutaline Sulfate Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d73080a4-4c14-40ec-89ec-fa42b09a1d69"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only</p>
<span class="Bold"><span class="Emphasis">A sterile aqueous solution for subcutaneous injection.</span></span><br>
</div>
<div class="Warning">
<a name="f08854ca-c431-44a9-96a9-042e069b0a13"></a><a name="section-2"></a><p></p>
<h1>WARNING: PROLONGED TOCOLYSIS<br>
</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48 to 72 hours).   In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting.  Serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported after administration of terbutaline sulfate to pregnant women.  In the mother, these adverse reactions include increased heart rate, transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>.  Increased fetal heart rate and <span class="product-label-link" type="condition" conceptid="23034" conceptname="Neonatal hypoglycemia">neonatal hypoglycemia</span> may occur as a result of maternal administration (see</span></span> <span class="Bold"><span class="Emphasis"><a href="#f83e0102-ff3f-401e-933f-c69fc850b25e">CONTRAINDICATIONS</a></span></span>, <span class="Bold Italics"><span class="Emphasis"><a href="#aaa8e0c2-c54f-43c4-ac93-bd6f29d0dfb6">Prolonged Tocolysis</a></span></span><span class="Bold"><span class="Emphasis">).</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="d55b3e40-4847-48c7-b091-f4715ee93d8d"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Terbutaline Sulfate Injection, USP, is a beta-adrenergic agonist bronchodilator available as a sterile, nonpyrogenic, aqueous solution in vials, for subcutaneous administration.  Each mL of solution contains: 1 mg of terbutaline sulfate USP (0.82 mg of the free base), and Water for Injection, USP.  Sodium chloride is used for isotonicity, and hydrochloric acid for adjustment to a pH of 3.0 to 5.0.  Terbutaline sulfate is (±)-α-[(<span class="Italics"><span class="Emphasis">tert</span></span>-butyl-amino) methyl]-3,5-dihydroxybenzyl alcohol sulfate (2:1) (salt). The structural formula is:</p>
<p><img alt="terbutaline_structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cec31032-f366-4524-9e01-63146e473b2b&amp;name=terbutaline-sulfate-injection-usp-figure-1-terbutaline_structure.jpg"> </p>
<p><span class="Bold"><span class="Emphasis">(C</span></span><span class="Bold"><span class="Emphasis"><span class="Sub">12</span></span></span><span class="Bold"><span class="Emphasis">H</span></span><span class="Bold"><span class="Emphasis"><span class="Sub">19</span></span></span><span class="Bold"><span class="Emphasis">NO</span></span><span class="Bold"><span class="Emphasis"><span class="Sub">3</span></span></span><span class="Bold"><span class="Emphasis">)</span></span><span class="Bold"><span class="Emphasis"><span class="Sub">2</span></span></span><span class="Bold"><span class="Emphasis"> • H</span></span><span class="Bold"><span class="Emphasis"><span class="Sub">2</span></span></span><span class="Bold"><span class="Emphasis">SO</span></span><span class="Bold"><span class="Emphasis"><span class="Sub">4        </span></span></span><span class="Bold"><span class="Emphasis">M.W. 548.65</span></span></p>
<p>Terbutaline sulfate USP is a white to gray-white crystalline powder.  It is odorless or has a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> odor of acetic acid.  It is soluble in water and in 0.1N hydrochloric acid, slightly soluble in methanol, and insoluble in chloroform.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="d64eea83-aab6-4e6f-8fed-385096d32045"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Terbutaline is a beta-adrenergic receptor agonist.  <span class="Italics"><span class="Emphasis">In vitro </span></span>and <span class="Italics"><span class="Emphasis">in vivo </span></span>pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta<span class="Sub">2</span>-adrenergic receptors.  While it is recognized that beta<span class="Sub">2</span>-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta<span class="Sub">2</span>-receptors in the human heart, existing in a concentration between 10% to 50%.  The precise function of these receptors has not been established (see <span class="Bold"><span class="Emphasis"><a href="#a965eca4-ccc4-4cc6-9935-b611b0d02464">WARNINGS</a></span></span>). Controlled clinical studies in patients given terbutaline subcutaneously have not revealed a preferential beta<span class="Sub">2</span>-adrenergic effect.</p>
<p>The pharmacologic effects of beta-adrenergic agonists, including terbutaline, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic 3’,5’-adenosine monophosphate (cAMP).  Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity</span> from cells, especially from mast cells.</p>
<p>Controlled clinical studies have shown that terbutaline relieves <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in acute and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> by significantly increasing pulmonary flow rates (e.g., an increase of 15% or more in FEV<span class="Sub">1</span>).  After subcutaneous administration of 0.25 mg of terbutaline, a measurable change in expiratory flow rate usually occurs within 5 minutes, and a clinically significant increase in FEV<span class="Sub">1</span> occurs within 15 minutes.  The maximum effect usually occurs within 30 to 60 minutes, and clinically significant bronchodilator activity may continue for 1.5 to 4 hours.  The duration of clinically significant improvement is comparable to that observed with equimilligram doses of epinephrine.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="b5489993-1216-467d-968d-c686da496155"></a><a name="section-3.1"></a><p></p>
<h2>Preclinical<br>
</h2>
<p class="First">Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (with histological evidence of <span class="product-label-link" type="condition" conceptid="4354249" conceptname="Myocardial necrosis">myocardial necrosis</span>) when beta-agonists and methylxanthines are administered concurrently. The clinical significance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e8914828-4926-4199-a769-dff3045837f9"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics<br>
</h2>
<p class="First">Subcutaneous administration of 0.5 mg of terbutaline to 17 healthy, adult, male subjects resulted in mean (SD) peak plasma terbutaline concentration of 9.6 (3.6) ng/mL, which was observed at a median (range) time of 0.5 (0.08 to 1) hours after dosing.  The mean (SD) AUC (0 to 48) and total body clearance values were 29.4 (14.2) hr • ng/mL, and 311 (112) mL/min respectively.  The terminal half-life was determined in 9 of the 17 subjects and had a mean (SD) of 5.7 (2) hours.  </p>
<p>After subcutaneous administration of 0.25 mg of terbutaline to two male subjects, peak terbutaline serum concentrations of 5.2 and 5.3 ng/mL were observed at about 20 minutes after dosing.</p>
<p>Elimination half-life of the drug in 10 of 14 patients was approximately 2.9 hours after subcutaneous administration, but longer elimination half-lives (between 6 to 14 hours) were found in the other 4 patients.  About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug.  It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="f933a7df-f4ad-4e87-8098-4ac81545c318"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Terbutaline Sulfate Injection, USP is indicated for the prevention and reversal of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients 12 years of age and older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and reversible <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> associated with <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="f83e0102-ff3f-401e-933f-c69fc850b25e"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="34070-3">
<a name="aaa8e0c2-c54f-43c4-ac93-bd6f29d0dfb6"></a><a name="section-5.1"></a><p></p>
<h2>Prolonged Tocolysis<br>
</h2>
<p class="First">Terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48 to 72 hours).  In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting (see <span class="Bold"><span class="Emphasis"><a href="#f08854ca-c431-44a9-96a9-042e069b0a13">BOXED WARNING</a></span></span>: <span class="Bold"><span class="Emphasis"><a href="#f08854ca-c431-44a9-96a9-042e069b0a13">PROLONGED TOCOLYSIS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="af682ce5-7ec2-4621-9e30-c5413501790e"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><br>
</h2>
<p class="First">Terbutaline sulfate injection is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a965eca4-ccc4-4cc6-9935-b611b0d02464"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="34071-1">
<a name="abec0f64-805e-47e8-a688-c00d23b0d213"></a><a name="section-6.1"></a><p></p>
<h2>Deterioration of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span><br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> may deteriorate acutely over a period of hours or chronically over several days or longer.  If the patient needs more doses of terbutaline than usual, this may be a marker of destabilization of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="e6332ee3-2566-4646-bd2c-63911eca3616"></a><a name="section-6.2"></a><p></p>
<h2>Use of Anti-Inflammatory Agents<br>
</h2>
<p class="First">The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in many patients.  Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="bd0b6095-d6a9-4ea0-8047-464584559f18"></a><a name="section-6.3"></a><p></p>
<h2>Cardiovascular Effects<br>
</h2>
<p class="First">Terbutaline, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms.  Although such effects are uncommon after administration of terbutaline at recommended doses, if they occur, the drug may need to be discontinued.  In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and <span class="product-label-link" type="condition" conceptid="4095285" conceptname="ST segment depression">ST segment depression</span>.  The clinical significance of these findings is unknown.  Therefore, terbutaline, like all sympathomimetic amines, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, especially coronary insufficiency, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a847c8c0-1d84-4dc4-b95a-3609e59c84dc"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span><br>
</h2>
<p class="First">There have been rare reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients receiving terbutaline; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> did not recur in these patients after the drug was discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d0c2676f-3a8a-4577-8fe1-d7e415e39ae4"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="f862b205-25c4-4f82-95da-bbcb1cf3c36f"></a><a name="section-7.1"></a><p></p>
<h2>General<br>
</h2>
<p class="First">Terbutaline, as with all sympathomimetic amines, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, including <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>; in patients with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; and in patients who are unusually responsive to sympathomimetic amines or who have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>. Significant changes in systolic and diastolic blood pressure have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.</p>
<p><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> and exacerbations of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> have been reported after terbutaline administration.  </p>
<p>Beta-adrenergic agonist medications may produce significant <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.  The decrease is usually transient, not requiring supplementation.</p>
<p>Large doses of intravenous terbutaline have been reported to aggravate pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f0c6dd7a-522e-4c58-981f-6ef154102f4b"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">The concomitant use of terbutaline with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient.</p>
<p><span class="Bold"><span class="Emphasis">Monoamine Oxidase Inhibitors or Tricyclic Antidepressants</span></span></p>
<p>Terbutaline should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline on the vascular system may be potentiated.</p>
<p><span class="Bold"><span class="Emphasis">Beta-Blockers</span></span></p>
<p>Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as terbutaline, but may produce severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients. Therefore, patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> should not normally be treated with beta-blockers.  However, under certain circumstances, e.g., as prophylaxis after <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.</p>
<p><span class="Bold"><span class="Emphasis">Diuretics</span></span></p>
<p>The ECG changes and/or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium-sparing diuretics.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a14911a7-7a58-4e19-8752-6149504757c1"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">In a 2-year study in Sprague-Dawley rats, terbutaline sulfate caused a significant and dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 50 mg/kg and above (approximately 810 times the maximum recommended daily subcutaneous (sc) dose for adults on a mg/m<span class="Sup">2</span> basis).  In a 21-month study in CD-1 mice, terbutaline showed no evidence of tumorigenicity at dietary doses up to 200 mg/kg (approximately 1,600 times the maximum recommended daily sc dose for adults on a mg/m<span class="Sup">2</span> basis).  The mutagenicity potential of terbutaline has not been determined.</p>
<p>Reproduction studies in rats using terbutaline demonstrated no impairment of fertility at oral doses up to 50 mg/kg (approximately 810 times the maximum recommended daily sc dose for adults on a mg/m<span class="Sup">2</span>  basis).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bb1db05d-83f6-47bb-a9e3-048d3a188fb0"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy: Teratogenic Effects<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Pregnancy Category C</span></span></p>
<p>There are no adequate and well-controlled studies of terbutaline sulfate in pregnant women.  Published animal studies show that rat offspring exhibit alterations in behavior and brain development, including decreased cellular proliferation and differentiation when dams were treated subcutaneously with terbutaline during the late stage of pregnancy and lactation period.  Terbutaline exposures in rat dams were approximately 24 to 48 times the common human dose in adults of 2 to 4 mg/day, on a mg/m<span class="Sup">2</span> basis.</p>
<p>Terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48 to 72 hours).  In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting.  Serious adverse reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported after administration of terbutaline sulfate to pregnant women.  In the mother, these adverse reactions include increased heart rate, transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>.  Increased fetal heart rate and <span class="product-label-link" type="condition" conceptid="23034" conceptname="Neonatal hypoglycemia">neonatal hypoglycemia</span> may occur as a result of maternal administration (see <span class="Bold"><span class="Emphasis"><a href="#f08854ca-c431-44a9-96a9-042e069b0a13">BOXED WARNING: PROLONGED TOCOLYSIS</a> </span></span>and <span class="Bold"><span class="Emphasis"><a href="#f83e0102-ff3f-401e-933f-c69fc850b25e">CONTRAINDICATIONS</a></span></span>, <span class="Bold Italics"><span class="Emphasis"><a href="#aaa8e0c2-c54f-43c4-ac93-bd6f29d0dfb6">Prolonged Tocolysi</a></span></span><span class="Bold Italics"><span class="Emphasis"><a href="#aaa8e0c2-c54f-43c4-ac93-bd6f29d0dfb6">s</a></span></span>). </p>
<p>In animal embryofetal developmental studies, no teratogenic effects were observed in offspring when pregnant rats and rabbits received terbutaline sulfate at oral doses up to 50 mg/kg/day, approximately 810 and 1600 times, respectively, the maximum recommended daily subcutaneous dose for adults, on a mg/m<span class="Sup">2</span> basis.</p>
<p>Terbutaline sulfate should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d72289ba-d1ed-4f67-b168-b2bf697556c4"></a><a name="section-7.5"></a><p></p>
<h2>Use in Labor and Deivery<br>
</h2>
<p class="First">Because of the potential for beta-agonist interference with uterine contractility, use of terbutaline for relief of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.</p>
<p>Terbutaline crosses the placenta.  After single dose IV administration of terbutaline to 22 women in late pregnancy who were delivered by elective Cesarean section due to clinical reasons, umbilical blood levels of terbutaline were found to range from 11% to 48% of the maternal blood levels.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e471b3b5-6580-4738-bae2-40e5b08832b1"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Therefore, terbutaline should be used during nursing only if the potential benefit justifies the possible risk to the newborn.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b87e2262-53e9-411e-b9ef-2848810d09e9"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">Terbutaline is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d8d9668e-9055-448a-8e61-da0bb44725ba"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use<br>
</h2>
<p class="First">Clinical studies of Terbutaline Sulfate Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b2b37022-40c8-4342-b51e-6e5a95ad7127"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions observed with terbutaline are similar to those commonly seen with other sympathomimetic agents.  All these reactions are transient in nature and usually do not require treatment.</p>
<p>The following table compares adverse reactions seen in patients treated with terbutaline (0.25 mg and 0.5 mg), with those seen in patients treated with epinephrine injection (0.25 mg and 0.5 mg), during eight double-blind crossover studies involving a total of 214 patients.</p>
<table><tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Incidence (%) of Adverse Reactions</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Terbutaline (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.25 mg</p>
<p>N=77</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.5 mg</p>
<p>N=205</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Reaction</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Central Nervous System</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">38</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">30.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Cardiovascular</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">22.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Respiratory</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Gastrointestinal</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Systemic</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushed</span> feeling</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at injection site</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Epinephrine (%)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.25 mg</p>
<p>N=153</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.5 mg</p>
<p>N=61</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Reaction</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Central Nervous System</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">31.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Cardiovascular</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">29.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Respiratory</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Gastrointestinal</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Systemic</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushed</span> feeling</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at injection site</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.6</p></td>
</tr>
</tbody></table>
<p><span class="Bold Italics"><span class="Emphasis">Note: </span></span>Some patients received more than one dosage strength of terbutaline and epinephrine.  In addition, there were reports of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (&lt;0.5%).  There have been rare reports of elevations in liver enzymes and of <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span> with terbutaline administration.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f160c739-f270-40ba-b17a-7d72747f4a29"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The median sc lethal dose of terbutaline in mature rats was approximately 165 mg/kg (approximately 2,700 times the maximum recommended daily sc dose for adults on a mg/m<span class="Sup">2</span> basis).  The median sc lethal dose of terbutaline in young rats was approximately 2,000 mg/kg (approximately 32,000 times the maximum recommended daily sc dose for adults on a mg/m<span class="Sup">2</span> basis).</p>
<p>The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under <span class="Bold"><span class="Emphasis"><a href="#b2b37022-40c8-4342-b51e-6e5a95ad7127">ADVERSE REACTIONS</a></span></span>, e.g., <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, angina, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> with rates up to 200 beats per minute, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may also occur.  There is no specific antidote.  Treatment consists of discontinuation of terbutaline together with appropriate symptomatic therapy.  The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  There is insufficient evidence to determine if dialysis is beneficial for overdosage of terbutaline.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="af569a3a-199d-4244-b215-5368388a664b"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Terbutaline Sulfate Injection, USP should be used only for subcutaneous administration and not intravenous infusion.  <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> and accurate dosing cannot be assured if the vials are not used in accordance with <span class="Bold"><span class="Emphasis"><a href="#af569a3a-199d-4244-b215-5368388a664b">DOSAGE AND ADMINISTRATION</a>.</span></span></p>
<p>Discard unused portion after single patient use.</p>
<p>The usual subcutaneous dose of Terbutaline Sulfate Injection, USP is 0.25 mg injected into the lateral deltoid area.  If significant clinical improvement does not occur within 15 to 30 minutes, a second dose of 0.25 mg may be administered.  If the patient then fails to respond within another 15 to 30 minutes, other therapeutic measures should be considered.  The total dose within 4 hours should not exceed 0.5 mg.</p>
<p><span class="Bold Italics"><span class="Emphasis">Note: </span></span>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="df0129c1-bdda-4507-818d-76614339a86e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">660501</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-665-01</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Terbutaline Sulfate Injection, USP, 1 mg/mL in a 2 mL amber, Type 1 glass vial, 25 vials per tray.</p></td>
</tr>
</tbody></table>
<p class="First">Discard unused portion after single patient use.</p>
<p>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
<p>Protect from light.  Do not use if solution is discolored.</p>
<p>Vial stoppers do not contain natural rubber latex.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a0ce00c1-d935-4d6b-ae75-9d10ec0cde31"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><img alt="app_logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cec31032-f366-4524-9e01-63146e473b2b&amp;name=terbutaline-sulfate-injection-usp-figure-2-add_band_logo.jpg"> </p>
<p>451001D</p>
<p>Revised: February 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="db5d222b-3a83-4db7-8cd4-265681538638"></a><a name="section-13"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - TERBUTALINE SULFATE 1 mL Single Use Vial Label</span></span><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-665-01</p>
<p>660501</p>
<p><span class="Bold"><span class="Emphasis">TERBUTALINE SULFATE INJECTION, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">1 mg/mL</span></span></p>
<p>For Subcutaneous Injection Only.</p>
<p>Sterile</p>
<p>Do not use if solution is discolored.</p>
<p>Protect from light.</p>
<p>Rx only</p>
<p><span class="Bold"><span class="Emphasis">1 mL</span></span> Single Use Vial</p>
<p><img alt="terbutaline_vlbl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cec31032-f366-4524-9e01-63146e473b2b&amp;name=terbutaline-sulfate-injection-usp-figure-3-terbutaline_vlbl.jpg"> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - TERBUTALINE SULFATE 1 mL Single Use Vial Tray Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-665-01</p>
<p>660501</p>
<p><span class="Bold"><span class="Emphasis">TERBUTALINE SULFATE INJECTION, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">1 mg/mL</span></span></p>
<p>For Subcutaneous Injection Only.</p>
<p>Do not use if solution is discolored.</p>
<p><span class="Bold"><span class="Emphasis">1 mL</span></span></p>
<p>Single Use Vial</p>
<p>Rx only</p>
<p><img alt="terbutaline_tray" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cec31032-f366-4524-9e01-63146e473b2b&amp;name=terbutaline-sulfate-injection-usp-figure-4-terbutaline_tray.jpg"> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TERBUTALINE SULFATE 		
					</strong><br><span class="contentTableReg">terbutaline sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-665</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TERBUTALINE SULFATE</strong> (TERBUTALINE) </td>
<td class="formItem">TERBUTALINE SULFATE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-665-01</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076887</td>
<td class="formItem">03/10/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>be203fdb-578c-49a1-8a77-b15b80377d75</div>
<div>Set id: cec31032-f366-4524-9e01-63146e473b2b</div>
<div>Version: 1</div>
<div>Effective Time: 20110304</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
